ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Cancer Pain Trial

Executive Summary

• ZYUS Life Sciences announced activation of two additional Canadian clinical sites—CancerCare Manitoba and The Research Institute of the McGill University Health Centre—bringing the Phase 2a UTOPIA‑1 trial to three active locations.
• The expansion broadens patient diversity and is expected to accelerate enrollment for Trichomylin® softgel capsules in advanced cancer pain patients.
• Management highlighted the milestone as a step toward generating safety and preliminary efficacy data needed for progression to later‑stage trials.

Key Details

• New Sites Activated: CancerCare Manitoba (CCMB) and The Research Institute of the McGill University Health Centre (The Institute).
• Existing Site: Centre Hospitalier de l'Université de Montréal (CHUM).
• Trial Design: Single‑arm, proof‑of‑concept Phase 2a study evaluating safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe pain.
• ClinicalTrials.gov Identifier: NCT06533657.
• Impact: Expansion to three sites is intended to increase enrollment speed and enhance demographic diversity of trial participants across Canada.
• Quote (President & CEO Brent Zettl): “Expanding the UTOPIA‑1 trial to three clinical sites marks a meaningful step forward in our mission to deliver safer, scientifically validated alternatives that have the potential to improve patient outcomes.”

Notable Quotes

• “The activation of these two additional clinical sites strengthens our clinical development program and advances our path toward generating preliminary efficacy and safety data needed to progress Trichomylin® softgel capsules into later‑stage trials.” – Brent Zettl, President and CEO

Materiality Assessment: Non‑Material – Positive (operational milestone that is favorable but does not yet constitute a material financial event).